Holen Sie sich die Stockscreener-App
14.88
0.93%
-0.14
Vorhandelsmarkt:
15.25
0.37
+2.49%
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
ANIK Stock Analysis: Anika Therapeutics Inc. gains 3.31 percent daily, trades at 14.98 dollar - Newser
Trading Systems Reacting to (ANIK) Volatility - Stock Traders Daily
ANIK Q1 2026 Earnings: Surprise Profit Swing as Anika Therapeutics Beats ExpectationsAnnual Earnings Summary - Newser
Why Is Anika Therapeutics, Inc. (ANIK) Stock Up Today? - Meyka
Anika Therapeutics Signals Momentum Amid Regulatory Risks - The Globe and Mail
Anika Therapeutics honors Clinical Trials Day as it advances patient outcomes - Traders Union
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN
Why Is Anika Therapeutics, Inc. (ANIK) Stock Down Today? - Meyka
Anika Therapeutics invites ESSKA Congress delegates to explore advances in HA-based cartilage repair - Traders Union
About Us | Oil & Gas JournalAnika Therapeutics Inc.Common Stock (Nasdaq:ANIK) Stock Quote - FinancialContent
TradingKey - TradingKey
How Anika Therapeutics Inc. (ANIK) Affects Rotational Strategy Timing - Stock Traders Daily
Anika Therapeutics (ANIK) Eps Diluted (TTM) - Zacks Investment Research
How Anika (ANIK) margins compare to industry leaders (+0.13%) 2026-05-08High Attention Stocks - newser.com
Anika Therapeutics explores why skin heals rapidly but tendons and cartilage lag in recovery - Traders Union
Number of shareholders of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Insider Buying: HENNEMAN JOHN B III Acquires 5,000 Shares of Ani - GuruFocus
Anika Therapeutics Q1 2026 earnings preview - MSN
Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada
Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com
Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan
President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance
Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - Minichart
ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative
Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co
Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus
Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock By Investing.com - Investing.com Australia
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock - Investing.com
Insider Purchase: President and CEO of $ANIK Buys 12,200 Shares - Quiver Quantitative
Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market - Stock Titan
Anika Therapeutics : 2026 Proxy Statement - marketscreener.com
Bullish On Anika Therapeutics’s Pullback As Integrity Scales (NASDAQ:ANIK) - Seeking Alpha
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Rotator cuff procedure advances driven by biology, Anika Therapeutics claims - Traders Union
(ANIK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript - Insider Monkey
Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss - Stock Titan
Anika Therapeutics Inc (ANIK) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments - GuruFocus
Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings - simplywall.st
Anika Therapeutics Signals Momentum Amid Regulatory Hurdles - TipRanks
1.92%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):